ASP 3291

Drug Profile

ASP 3291

Alternative Names: ASP3291

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Developer Telsar Pharma
  • Class Anti-inflammatories; Cyclic peptides
  • Mechanism of Action Melanocortin type 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Ulcerative colitis

Most Recent Events

  • 01 Apr 2014 Telsar Pharma completes a phase II trial in Ulcerative colitis in USA, Canada, Israel and Serbia (NCT01612039)
  • 17 Jan 2014 Telsar Pharma completes enrolment in its phase II trial for Ulcerative colitis in USA (NCT01612039)
  • 01 Jul 2012 Phase-II clinical trials in Ulcerative colitis in Canada, Israel and Serbia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top